KR20240042402A - 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 - Google Patents

경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 Download PDF

Info

Publication number
KR20240042402A
KR20240042402A KR1020247000323A KR20247000323A KR20240042402A KR 20240042402 A KR20240042402 A KR 20240042402A KR 1020247000323 A KR1020247000323 A KR 1020247000323A KR 20247000323 A KR20247000323 A KR 20247000323A KR 20240042402 A KR20240042402 A KR 20240042402A
Authority
KR
South Korea
Prior art keywords
bumetanide
pharmaceutical composition
subject
salt
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000323A
Other languages
English (en)
Korean (ko)
Inventor
발라싱암 라다크리슈난
벤 에스크
웨이 린
앤드루 셴 천
Original Assignee
레스큐 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레스큐 파마슈티컬스 엘엘씨 filed Critical 레스큐 파마슈티컬스 엘엘씨
Publication of KR20240042402A publication Critical patent/KR20240042402A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
KR1020247000323A 2021-06-09 2022-06-09 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 Pending KR20240042402A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
KR20240042402A true KR20240042402A (ko) 2024-04-02

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000323A Pending KR20240042402A (ko) 2021-06-09 2022-06-09 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법

Country Status (10)

Country Link
US (1) US20240285566A1 (cg-RX-API-DMAC10.html)
EP (1) EP4351554A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024520788A (cg-RX-API-DMAC10.html)
KR (1) KR20240042402A (cg-RX-API-DMAC10.html)
CN (1) CN117915905A (cg-RX-API-DMAC10.html)
AU (1) AU2022289724A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025880A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221710A1 (cg-RX-API-DMAC10.html)
IL (1) IL309160A (cg-RX-API-DMAC10.html)
WO (1) WO2022261344A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
EP2086329B1 (en) * 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
CA3160278A1 (en) * 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics

Also Published As

Publication number Publication date
EP4351554A4 (en) 2025-05-07
JP2024520788A (ja) 2024-05-24
IL309160A (en) 2024-02-01
US20240285566A1 (en) 2024-08-29
AU2022289724A1 (en) 2024-01-18
EP4351554A1 (en) 2024-04-17
CA3221710A1 (en) 2022-12-15
WO2022261344A8 (en) 2023-02-02
WO2022261344A1 (en) 2022-12-15
CN117915905A (zh) 2024-04-19
BR112023025880A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
JP7048576B2 (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
TWI815796B (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
US20120040970A1 (en) Intranasal delivery system for dantrolene
JP2023533129A (ja) 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法
US20240285566A1 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
CN101647774A (zh) 一种细辛脑注射剂及其制备方法
ES2396502T3 (es) Formulaciones para la administración terapéutica de la hormona estimulante de la tiroides (TSH)
JP2024526357A (ja) 水性ブメタニド含有液体
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
US10201552B2 (en) Method of increasing the bioavailability of an HIV drug
US20250319070A1 (en) Losartan liquid formulations and methods of use
Ichai et al. Sodium disorders
CN120713836A (zh) 一种尼莫地平注射液及其制备方法
HK1208372A1 (en) Liquid formulation

Legal Events

Date Code Title Description
PA0105 International application
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250609

Comment text: Request for Examination of Application